TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00024050
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00024050
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01178320
Drug: Simvastatin, simvastatin plus extended-release niacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be enrolled in this substudy only if they are candidates for the main AIM-HIGH study (NCT00120289). Participants will be randomly assigned to simvastatin or simvastatin plus niacin as a part of the main AIM-HIGH protocol, and adjustments in simvastatin and/or niacin doses will be made as per the protocol for the main AIM-HIGH study.
Study: NCT03099499
Drug: ONC201
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONC201 will be administered at a dose of 625 mg by mouth weekly until disease progression, unacceptable toxicity, or if the patient discontinues for any other reason. Radiologic tumor assessment would be performed at baseline, Cycle 3 Day 1, Cycle 5 Day 1, and at the end of every 3 cycles beyond cycle 5. All patients including those removed from the study due to unacceptable toxicity, will undergo radiologic tumor assessment at the time of discontinuation (End of treatment).
Study: NCT00280501
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02793011
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo liquid (Ora-sweet or simple syrup) or Placebo capsule
Study: NCT00005863
Drug: tretinoin
Normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00075673
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients receive oral celecoxib twice daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Study: NCT00978432
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day for Part 1 of the trial
Study: NCT00978432
Drug: LBH589
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg on Monday, Wednesday and Friday weekly for Part 1 of the trial
Study: NCT00683332
Drug: Tigecycline (Tygacil)
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This is a non-interventional study; patients are administered Tygacil as prescribed by their doctor as per registered indications stated in product label/insert (50 mg by Intravenous Injection).
Study: NCT04505397
Drug: SKL24741
Approvals — FDA: no, EMA: no, PMDA: no
Description: An inhibitor of voltage-gated sodium channels and a possible activator of Big Potassium channels. Administered as an oral dose in the form of a capsule or tablet.
Study: NCT04505397
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill manufactured to mimic SKL24741
Study: NCT01168700
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1.2 g per day for 12 weeks.
Study: NCT02752971
Drug: Sodium diclofenac
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03028350
Drug: Placebo Oral Capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be treated with oral placebo daily for 8 weeks
Study: NCT00084617
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally
Study: NCT03703570
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT03776487
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04643457
Drug: UCB9741
Approvals — FDA: no, EMA: no, PMDA: no
Description: - Pharmaceutical form: Solution Participants will receive UCB9741 during the Treatment Period.
Study: NCT04643457
Drug: Intravenous Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: - Pharmaceutical form: Solution Participants will receive Placebo to maintain the blinding during the Treatment Period.
Study: NCT04643457
Drug: Subcutaneous Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution Participants will receive subcutaneous Placebo to maintain the blinding during the Treatment Period.
Study: NCT00552526
Drug: Antiepileptic drug (AED)
Normalized name: ANTIEPILEPTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: An AED,not used by the patient before, which we consider to be the most appropriate will be given orally or by gastrostomy. Serum concentration, the body weight, side effects and effects on the epilepsy will be considered when deciding the dose of the AED. Traditions for amount of medicine/kg body weight or optimal serum concentration at our center will be followed. This tradition will be the same as in other major European epilepsy centers but might propose lower, but not higher amounts than recommended by the drug company. Drugs from ACT groups N03A, N05BA, N05CD, H02A or S01EC will be used including prednisolon,levetiracetam, valproate, carbamazepine, oxcarbazepine, topiramate, felbamate, zonisamide, vigabatrin, tiagabil, lamotrigine, pregabalin, rufinamide, clobazam, clonazepam, tiagabine, gabapentin, phenytoin, phenobarbital, ethosuximide, acetazolamide, nitrazepam and other new antiepileptic drugs that might be released during the study period.
Study: NCT00745199
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule contains 135 mg lactose, 1 capsule 3 times daily for 8 weeks
Study: NCT00151970
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch 10mg/12.5cm2, 15mg/18.75cm2, 20mg/25cm2, and 30mg/37.5cm2 patch sizes applied daily
Study: NCT01364675
Drug: Metformin+Enalapril+Simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poly-pill - composed of Metformin (500 mg), Enalapril (10 mg) and Simvastatin (10 mg) in single tablet given once daily after dinner for 4 years
Study: NCT01364675
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical Placebo Tablet
Study: NCT04562025
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 times of cell-free stem cell suspension (saline containing 1% human albumin/100mL intravenously at week 1, week 2, week 3).
Study: NCT01315236
Drug: Liposomal amikacin for inhalation (LAI)
Normalized name: amikacin liposomal Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.~* 590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.~* Administration time is approximately 13 minutes.~* Liposomal amikacin for inhalation will be administered for 84 days in the double-blind, randomized portion of the study.~* Subjects can continue with 84 additional days of dosing in the open label extension.
Study: NCT01315236
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Placebo is provided as a sterile aqueous lipid dispersion for inhalation via nebulization.~* Administration procedures, volume and administration time are similar to LAI.~* Placebo will be administered for 84 days only during the double-blind, randomized portion of the study.
Study: NCT02221622
Drug: Placebo injection (intravenous solution)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intravenous infusion
Study: NCT03191578
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of placebo
Study: NCT02628665
Drug: photosensitizer(photofrin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: photosensitizer(photofrin): 2mg/kg
Study: NCT00926588
Drug: Stepped care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured algorithms for stepped care analgesic management and explicit decision rules for adjusting treatment are new tools developed for this study.
Study: NCT02145507
Drug: SOLX (Investigational)
Normalized name: INVESTIGATIONAL AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOLX is regulated as a drug but is not intended to provide a direct therapeutic benefit.
Study: NCT00470184
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral
Study: NCT01131351
Drug: Optimized Background Regimen (OBR)
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: OBR was selected at the discretion of the study investigator and included at least 2 anti-TB medications based on World Health Organization (WHO's) guidelines for the programmatic management of drug-resistant TB. Study investigator could change OBR for a participant based on his/her tolerability and drug susceptibility testing (DST) results.
Study: NCT03590197
Drug: Melatonin 3 mg
Normalized name: melatonin 3 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin 3 mg/ day with Valproate
Study: NCT04314531
Drug: matching placebo injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: one 1 mL injection of placebo
Study: NCT02079090
Drug: Fentofol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 microgram/kg Fentanyl, and 2 minutes later receive 1 mg/kg Propofol (Diprivan)
Study: NCT04296279
Drug: FMP014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Falciparum Malaria Protein-14
Study: NCT01082640
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat placebo-matching capsules
Study: NCT01143272
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01358019
Drug: LY2523355
Approvals — FDA: no, EMA: no, PMDA: no
Description: Days 1, 2, and 3 in a cycle that consists of 21-days
Study: NCT01251406
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily subcutaneous administration for 8 hours a day for 10 days
Study: NCT01251406
Drug: rhNRG-1 Dose 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily subcutaneous administration for 8 hours a day for 10 days
Study: NCT01251406
Drug: rhNRG-1 Dose 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily subcutaneous administration for 8 hours a day for 10 days
Study: NCT01411670
Drug: Placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment
Study: NCT00745225
Drug: placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule daily, 96 weeks.
Study: NCT02235259
Drug: XG-104
Normalized name: Ninjacof XG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of XG-104 (3 concentrations) versus placebo eye drops efficacy
Study: NCT02235259
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02704546
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules identical in shape, colour and size to the Ritalin® capsules, which contain only the inactive ingredients of the same formulation.
Study: NCT01931748
Drug: MELSMON
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02107937
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin and Paclitaxel is Standard of Care First Line Chemotherapy
Study: NCT01931748
Drug: UNCNT
Normalized name: Unspecified Contraceptive
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01595984
Drug: cyclosporin + mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: antirejection drug, renal transplantation
Study: NCT01595984
Drug: everolimus + mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: antirejection drug, renal transplantation
Study: NCT01809132
Drug: Zinc Sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc Sulfate, nutritional supplement
Study: NCT04111536
Drug: liothyronine
Normalized name: Liothyronine
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each treatment period of liothyronine was approximately 8 weeks in duration, with weekly titration of study drug for four weeks, followed by a maintenance dose for 4 weeks, then 2-week washout before crossing over to receive the alternate therapy - placebo.
Study: NCT00108186
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eight subjects will be assigned to one of three cohorts. Subjects will receive Celecoxib in escalating doses per cohort, starting with 200mg twice a day by mouth; 400mg twice a day by mouth; and increasing to 600mg twice a day by mouth, for a total of 7 days. Subjects will have blood taken before the start of Celecoxib, and after completion of 7-days of Celecoxib.
Study: NCT06041399
Drug: hypoglycemic Agents(metformin)
Normalized name: ORAL HYPOGLYCEMIC AGENTS,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients treated with hypoglycemic Agents(metformin)
Study: NCT06041399
Drug: lipid-lowering drug(Statin)
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients treated with lipid-lowering drug(Statin)
Study: NCT01641237
Drug: no added fluoride in a silica base
Approvals — FDA: no, EMA: no, PMDA: no
Description: no added fluoride
Study: NCT02398448
Drug: Zyloprim® 300 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04526691
Drug: KEYTRUDA®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion Q3W on Day 1 of each 21-day cycle (fixed pembrolizumab dose 200 mg Q3W)
Study: NCT01875003
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lebrikizumab matching placebo will be administered as SC injection Q4W.
Study: NCT01875003
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will continue to receive ICS therapy (total daily dose of 500-2000 mcg fluticasone propionate DPI or equivalent) along with at least one second controller medications (e.g. long-acting beta agonists \[LABAs\], leukotriene receptor antagonists (LTRAs), long-acting muscarinic antagonists (LAMAs), or theophylline) as standard of care.
Study: NCT01993251
Drug: melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: one capsule, melatonin 0.5 mg, oral, once a day, 30 minutes before bedtime
Study: NCT01993251
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: one capsule, melatonin 2 mg, oral, once a day, 30 minutes before bedtime
Study: NCT01993251
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: one capsule, melatonin 6 mg, oral, once a day, 30 minutes before bedtime
Study: NCT01993251
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one capsule, placebo, oral, once a day, 30 minutes before bedtime
Study: NCT02288143
Drug: COOL-COS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled ovarian stimulation will start on the second or third day of a menstrual cycle:~* Oral clomiphene citrate: 100 mg/day until the day of the triggering.~* Oral letrozole: 7.5 mg/day during the first 5 days of the controlled ovarian stimulation.~* hMG: 150 IU every other day beginning on the day 6 of the controlled ovarian stimulation.~The triggering will be performed using urinary hCG (5,000 IU subcutaneous).~* 1-2 days after the identification of one follicle ≥ 17 mm~* 0-1 days after the identification of one follicle ≥ 19 mm.
Study: NCT01231854
Drug: Alitretinoin
Normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In accordance with the current guideline management of hand eczema alitretinoin will be administered orally in a constant daily dosage of 30 mg.
Study: NCT01423656
Drug: LEO 29102
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01423656
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator: LEO 29102 vehicle
Study: NCT00513565
Drug: single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive single doses of GSK561679, lorazepam, or placebo at each treatment session.
Study: NCT00678379
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Submucosal injection of 1.5 mL into each tonsillar fossa prior to performing tonsillectomy.~A - normal saline
Study: NCT00009061
Drug: GW433908
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00644553
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin Extended-Release 500 mg tablet (2 tablets QD)
Study: NCT00143091
Drug: CP-316,311
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00143091
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02432313
Drug: Modified Release Formulation x (MRx)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject receives 1 dose of a MRx and is followed. 7-day washout before dosing with another formulation
Study: NCT01407575
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matched placebo
Study: NCT01062139
Drug: Xarlin (Levocetirizine)
Normalized name: BLACK MARLIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy compared to mono therapy
Study: NCT01062139
Drug: Cosalin (Petasites hybridus CO2 extract)
Normalized name: Cosamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy compared to mono therapy
Study: NCT00380770
Drug: Generic HAART Triomune : d4T, 3TC, NVP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triomune® (Cipla, Mumbai) Stavudine 40mg b.d \> 60 kg , 30mg bd \<60kg Lamivudine 150mg b.d \> 50 kg 2mg/kg \< 50 kg Nevirapine 200mg b.d ( 200mg daily for first 2 weeks)
Study: NCT00380770
Drug: Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triomune® (Cipla, Mumbai) Stavudine 40mg b.d \> 60 kg , 30mg bd \<60kg Lamivudine 150mg b.d \> 50 kg 2mg/kg \< 50 kg Nevirapine 200mg b.d ( 200mg daily for first 2 weeks) Intramuscular Bleomycin 10 U/m2 ; Intravenous Vincristine 1.4mg/m2 maximum 2mg and Intravenous Doxorubicin 20mg/m2.
Study: NCT04536831
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D will be given to group B slected by Lottery method
Study: NCT04428775
Drug: ALZT-OP1a (cromolyn)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Mast cell stabilizer~2. Neuroinflammatory microglial modulator~3. anti-inflammatory
Study: NCT00044551
Drug: Taxane (Cytotoxic, BAY59-8862)
Normalized name: acetaminophen / oxycodone hydrochloride Oral Capsule [Taxadone]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily 1 h infusion every 3 weeks
Study: NCT01859585
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac 30 mg intravenous
Study: NCT01905124
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets orally every 12 hours for 24 weeks
Study: NCT03203499
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered orally.
Study: NCT02709590
Drug: diclofenac potassium + lidocaine
Normalized name: diclofenac / lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will have of oral diclofenac potassium 60 minutes before the procedure plus lidocaine anesthetic cream placed into their cervix immediately before HSG
Study: NCT02709590
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will have of oral placebo tablet 60 minutes before the procedure plus placebo cream placed into their cervix immediately before HSG
Study: NCT01383096
Drug: OZ439 mesylate 800mg Powder in Bottle for Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: OZ439 800 mg (as free base) as powder in a bottle for reconstitution in a suspension prior to oral administration
Study: NCT00087399
Drug: antidepressant
Normalized name: Antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03847207
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo Solution
Study: NCT00752115
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tab, day 1,8 and 15 in each cycle.
Study: NCT03862040
Drug: Standard of Care Antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care antibiotic treatment for pneumonia
Study: NCT04684524
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Injection solution Route of administration: Subcutaneous
Study: NCT02928497
Drug: Single Antiplatelet Therapy or No Therapy (Control)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Antiplatelet Therapy or No Therapy at the discretion of the study physician.
Study: NCT03660488
Drug: Benzathine Penicillin G
Normalized name: Benzathine penicillin G
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control group will receive Benzathine Penicillin G 2.4 Million Units intramuscularly for treatment of syphilis. Penicillin is the indicated treatment for syphilis infection
Study: NCT00894465
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children are randomized to receive a placebo prior to undergoing VCUG
Study: NCT04569032
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/m\^2 administered intravenously (IV; into the vein) on Day 1 of each 21 -day cycle
Study: NCT04569032
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/m\^2 administered intravenously (IV; into the vein) on Day 1 of each 21 -day cycle
Study: NCT00909181
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Gel Oxybutynin Gel. Transdermal gel was applied once-daily (in the morning) during 12 weeks of treatment.~Evaluation: reduction of incontinent episodes (baseline vs 12 weeks); comparison 56 resp. 84 mg vs placebo
Study: NCT00404066
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/m2, intravenously every 2 weeks for 4 cycles. Given as first treatment with cyclophosphamide.
Study: NCT00404066
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m2, intravenously every 2 weeks for 4 cycles. Given as first treatment with doxorubicin.
Study: NCT00298467
Drug: MDX-060
Normalized name: hydrocortisone acetate Topical Gel [Cortisil MDX]
Approvals — FDA: no, EMA: no, PMDA: no